T. Rowe Price Associates’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18K | Sell |
12,400
-25,743
| -67% | -$37.4K | ﹤0.01% | 3047 |
|
|
2025
Q1 | $62K | Hold |
38,143
| – | – | ﹤0.01% | 2898 |
|
|
2024
Q4 | $138K | Sell |
38,143
-353,861
| -90% | -$1.28M | ﹤0.01% | 2774 |
|
|
2024
Q3 | $2.24M | Buy |
392,004
+329,697
| +529% | +$1.88M | ﹤0.01% | 1579 |
|
|
2024
Q2 | $288K | Sell |
62,307
-2,053,170
| -97% | -$9.49M | ﹤0.01% | 2437 |
|
|
2024
Q1 | $17.3M | Sell |
2,115,477
-443,003
| -17% | -$3.62M | ﹤0.01% | 1011 |
|
|
2023
Q4 | $14.5M | Buy |
2,558,480
+372,021
| +17% | +$2.1M | ﹤0.01% | 1023 |
|
|
2023
Q3 | $4.07M | Sell |
2,186,459
-642,146
| -23% | -$1.19M | ﹤0.01% | 1216 |
|
|
2023
Q2 | $7.78M | Sell |
2,828,605
-46,769
| -2% | -$129K | ﹤0.01% | 1105 |
|
|
2023
Q1 | $9.03M | Sell |
2,875,374
-49,879
| -2% | -$157K | ﹤0.01% | 1075 |
|
|
2022
Q4 | $17.3M | Sell |
2,925,253
-38,803
| -1% | -$229K | ﹤0.01% | 950 |
|
|
2022
Q3 | $26M | Sell |
2,964,056
-1,419,107
| -32% | -$12.4M | ﹤0.01% | 829 |
|
|
2022
Q2 | $33M | Buy |
4,383,163
+5,791
| +0.1% | +$43.7K | ﹤0.01% | 1012 |
|
|
2022
Q1 | $106M | Buy |
4,377,372
+292,574
| +7% | +$7.1M | 0.01% | 713 |
|
|
2021
Q4 | $132M | Buy |
4,084,798
+127,055
| +3% | +$4.09M | 0.01% | 680 |
|
|
2021
Q3 | $177M | Buy |
3,957,743
+412,906
| +12% | +$18.4M | 0.02% | 581 |
|
|
2021
Q2 | $134M | Buy |
3,544,837
+1,447,028
| +69% | +$54.8M | 0.01% | 682 |
|
|
2021
Q1 | $77.6M | Buy |
2,097,809
+567,767
| +37% | +$21M | 0.01% | 850 |
|
|
2020
Q4 | $49.4M | Buy |
+1,530,042
| New | +$49.4M | 0.01% | 968 |
|